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Abstract
C-reactive Protein (CRP) measurements above 10 mg/L have been conventionally treated as acute inflammation and
excluded from epidemiologic studies of chronic inflammation. However, recent evidence suggest that such CRP elevations
can be seen even with chronic inflammation. The authors assessed 3,300 participants in The Coronary Artery Risk
Development in Young Adults study, who had two or more CRP measurements between 1992/3 and 2005/6 to a)
investigate characteristics associated with repeated CRP elevation above 10 mg/L; b) identify subgroups at high risk of
repeated elevation; and c) investigate the effect of different CRP thresholds on the probability of an elevation being one-
time rather than repeated. 225 participants (6.8%) had one-time and 103 (3.1%) had repeated CRP elevation above 10 mg/L.
Repeated elevation was associated with obesity, female gender, low income, and sex hormone use. The probability of an
elevation above 10 mg/L being one-time rather than repeated was lowest (51%) in women with body mass index above
31 kg/m2, compared to 82% in others. These findings suggest that CRP elevations above 10 mg/L in obese women are likely
to be from chronic rather than acute inflammation, and that CRP thresholds above 10 mg/L may be warranted to
distinguish acute from chronic inflammation in obese women.
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Introduction
With growing evidence linking chronic inflammation to various
major disease processes, interest in C-Reactive Protein (CRP) - a
robust marker of systemic inflammation – has increased sharply.
Efforts to elucidate the role of CRP in cardiovascular and other
disease processes have necessitated consideration of how to
interpret very high levels of CRP, specifically whether values
above a certain level (e.g., 10 mg/L) reflect acute inflammation,
such as due to recent or ongoing infection, and should therefore
not be used as a marker of chronic inflammation. Clinical
guidelines recommend repeat CRP measurement (after at least 2
weeks) in those with an initial reading .10 mg/L, to distinguish
between short-term and more sustained elevation [1–3]. In
research studies, the current convention is to exclude those with
CRP .10 mg/L [3]. However, there are multiple reasons to
question the 10 mg/L threshold for distinguishing acute from
chronic inflammation. First, CRP values greater than 10 mg/L
are not uncommon; multiple studies indicate that 5% or more of
the population has such values [4–7]. Second, some data suggest
that even a one-time CRP value .10 mg/L does have long-term
health implications. Indeed, individuals with CRP .10 mg/L had
the highest risk of future vascular events in several cohorts,
including healthy middle-aged women [4], middle-aged men and
women [8], older men and women [9], and post-stroke patients
[10]. Thus, CRP values .10 mg/L might indicate chronic
inflammation in a large proportion of individuals, and this may
especially be so in people with characteristics such as obesity and
smoking, which are known risk factors for chronic inflammation.
Accordingly, our objective was to determine what proportion of
patients, among those who do not report being sick recently, have
CRP .10 mg/L; whether this proportion varies by patient
characteristics; whether these patients actually show evidence of
sustained CRP elevation over several years; and if a higher
threshold could be used to improve the identification of those with
one-time elevation. The latter, if found, would have important
implications for the current practice of treating CRP values over
10 mg/L as indicative of acute infection and excluding them from
analyses. To the extent that we find that many CRP values over
10 mg/L are, in fact, more likely indicative of chronically high
levels, exclusion of such values from analyses should be re-
considered.
Methods
Study Design and Population
The Coronary Artery Risk Development in Young Adults
(CARDIA) is a bi-ethnic, prospective, multi-center study of the
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evolution of cardiovascular risk beginning in young adulthood. In
1985–1986, 5,115 participants, aged 18 to 30 years, were recruited
at Birmingham, AL; Chicago, IL; Minneapolis, MN; and
Oakland, CA, to achieve a balance at each site by race (black,
white), gender, education (high school degree or less, more than
high school), and age (18–24 years, 25–30 years [11]). Follow-up
examinations occurred during 1987–1988 (Year 2), 1990–1991
(Year 5), 1992–1993 (Year 7), 1995–1996 (Year 10), 2000–2001
(Year 15), and 2005–2006 (Year 20). A majority of the surviving
group has been examined at each follow-up (91%, 86%, 81%,
79%, 74%, and 72%, respectively). Before exclusions (detailed
below), 4,086 participants who were examined at year 7 were
eligible for this analysis. Serum CRP measurements were made in
Years 7, 15, and 20. CRP values of those reporting having been
sick during the 24 hours preceding their blood draw were coded as
missing for that year – 8.8% (n= 355) for Year 7, 7.9% (n= 266)
for Year 15 and 5.6% (n= 179) for Year 20, for a total of 800
excluded CRP measurements. In total, 167 participants were
completely excluded from the analysis because they reported
having been sick at one or more than one visits. Inclusion in the
present analyses required availability of valid CRP data (when not
sick in the previous 24 hours) on at least two of the three visits in
years 7, 15 and 20 (n= 3,354). Those who were pregnant (n = 50)
or had self-reported coronary artery disease (n = 4) at Year 7 were
excluded, leaving a sample size of 3,300. The study was approved
by an institutional review board at each CARDIA study site
(Birmingham, AL; Chicago, IL; Minneapolis, MN; and Oakland,
CA). All participants provided written informed consent at each
examination. Detailed study design and cohort descriptions are
available [12].
Measurements: C-Reactive Protein
Plasma CRP assays for all samples were done using the BNII
nephelometer from Dade Behring utilizing a particle enhanced
immunonepholometric assay; the assay range is 0.175-1,100 mg/
L, intra-assay coefficients of variation 2.3–4.4% and inter-assay
coefficients of variation 2.1–5.7%. Technical error (including
handling, storage, and assay variation) in blinded duplicate
plasma aliquots at years 15 and 20 was 18.5% and 20.4%,
respectively.
We defined one-time CRP elevation as having CRP .10 mg/L
at exactly one visit, and repeated elevation as having CRP
.10 mg/L at two or more visits.
Measurements: Predictors of CRP Elevation
The predictors considered were participant characteristics at the
initial CRP evaluation (Year 7), pre-specified based on literature
review.
Socio-demographic variables examined were gender, race (African-
American vs. Caucasian), pre-tax family income (Less than 25,000
dollars a year; 25,000 to 50,000; 50,000 to 75,000; and more than
75,000), and highest education grade completed (High School or
Less, College Only, or Graduate School).
Health Behavior variables. Smoking status was coded as
never-smoker, past-smoker, and current-smoker. A physical
activity intensity score was computed by multiplying reported
frequency of engagement in 13 exercise and recreation activities
by the intensity of the activity [13]. Consumption of wine, beer,
and liquor was assessed and summed to create an index of total
alcohol consumption (ml/day). The total alcohol consumption was
then categorized as non-drinker, moderate-drinker (0.1–12 ml/
day) or severe-drinker (.12 ml/day).
Health status. Participants were asked about doctor-
diagnosed high blood pressure, diabetes, high cholesterol,
asthma, chronic obstructive pulmonary disease and cancer.
Asthma and chronic obstructive pulmonary disease were
combined into a binary variable, respiratory conditions.
Information was also collected on medications for hypertension,
aspirin, oral contraceptive pills and hormone replacement therapy.
Use of oral contraceptive pills and hormone replacement therapy
were combined into a binary variable, use of sex hormones. Body
mass index (BMI) was calculated from measured height and
weight.
Analyses
Analyses were undertaken to answer the following three
questions:
1. What patient characteristics are associated with CRP elevation
above 10 mg/L one or more times, relative to no CRP
elevation above 10 mg/L?
2. Of those with CRP elevated above 10 mg/L one or more
times, are certain patient characteristics associated with greater
likelihood of the CRP elevation being repeated rather than a
one-time elevation?
3. Can we improve the identification of one-time CRP elevation
by using different CRP thresholds in different groups?
First, the associations of socio-demographic, health status, and
health behavior characteristics with the odds of CRP elevation
above 10 mg/L one or more times (relative to no CRP elevation
above 10 mg/L) were examined using multinomial logistic
regression. Physical activity, BMI and age were included as
continuous variables; the rest as categorical. In addition, we
included a quadratic term for BMI (BMI was centered at the mean
and then squared) and two gender by variable interactions (i.e.,
gender by BMI and BMI-squared) based on literature review
[5,7,14–20].
Second, we examined the odds of repeated CRP elevation
among those who had at least one episode of CRP elevation above
10 mg/L, as a function of the same demographic/health/lifestyle
characteristics, using logistic regression. The model was made
parsimonious using backward selection based on the Akaike
Information Criterion [21]. A generalized Spearman correlation
was used to identify the two most influential predictor variables in
the logistic regression model [22]. Next, using the two most
influential variables as predictors, regression tree analysis was
performed to identify subgroups at high risk for CRP elevations
being repeated rather than one-time elevations [23].
Finally, we examined the effects of various CRP thresholds on
the probability of above-threshold elevations being one-time
elevations in sub-groups defined by the two characteristics that
were most influential in the logistic regression model.
Analyses used R statistical software version 2.9.0 (R Foundation,
Vienna, Austria). All statistical tests were two-sided, and a P-value
less than 0.05 was considered statistically significant.
Results
The study sample (n = 3,300) was representative of the complete
CARDIA Year 7 sample (n = 4,086) with respect to clinical
characteristics at baseline. In the study sample, 2,972 (90.1%) had
no episode of CRP elevation above 10 mg/L, while 225 (6.8%)
had one-time elevation and 103 (3.1%) had elevation on at least
two occasions (Table 1). Among the 3,300 participants included,
471 (14.3%) reported being sick at one visit, of whom 41 (8.7%)
had CRP elevation at one or more non-sick visits. The prevalence
of CRP elevation above 10 mg/L did not increase from year 7
Repeated CRP Elevation Above 10 mg/L
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(4.3%) to year 20 (3.7%). Of the 225 participants with one-time
elevation above 10 mg/L, only 60 (1.8% of 3,300, 26.7% of 225)
had no other CRP readings above 3 mg/L; the other 165 had at
least one other reading above 3 mg/L, and 96 of them had at least
one other reading above 6 mg/L, suggesting chronic rather than
acute inflammation.
Multinomial logistic regression of one-time and repeated CRP
elevation (relative to no CRP elevation above 10 mg/L)
demonstrated that higher income was associated with decreased
odds of repeated CRP elevation, and both current and past
smoking were associated with increased odds of one-time CRP
elevation. Women were more likely than men to have both one-
Table 1. Baseline (year 7) Characteristics of 3,300 Participants in the CARDIA Study, According to the C-reactive Protein (CRP)
Categories*{.
Characteristics
No CRP elevation above
10 mg/L One-time CRP elevation Repeated CRP elevation
N=2972 N= 225 N= 103
Age(years) 33(29,35) 33(30,35) 32(29,35)
Gender
male 47.6 29.3 11.7
female 52.4 70.7 88.4
Race
Caucasian 56.0 40.4 24.3
African-American 44.0 59.6 75.7
Income
,$25 K/year 30.4 37.7 54.4
$25-$50 K/year 36.9 39.6 33.0
$50-$75 K/year 18.0 14.1 11.7
.$75 K/year 14.8 8.6 1.0
Education
high school 26.1 30.8 35.9
college 54.1 52.9 55.3
graduate school 19.9 16.3 8.7
Smoking status
current smoker 24.2 30.7 29.4
former smoker 15.8 20.0 12.8
Physical activity (100 EU) 2.8(1.4,4.9) 2.1(1.1,4.3) 1.6(0.6,3.0)
Alcohol use{
non-drinker 44.2 48.9 62.8
,1 glass a day 28.2 24.9 17.7
.=1 glass a day 27.6 26.2 19.6
Body mass index (kg/m2) 25.1(22.4,28.6) 29.1(25.4,34.8) 35.8(30.8,41.5)
Comorbidities 1
hypertension 9.0 12.4 24.3
diabetes mellitus 3.1 4.9 4.9
hyperlipidemia 11.8 11.3 12.9
respiratory conditions || 10.8 14.8 18.6
cancer 1.9 2.7 0
Medication use
sex hormones " 22.5 28.3 24.2
aspirin 3.5 3.6 1.9
anti-hypertensives 1.4 2.2 4.9
Abbreviations; K, 1,000: EU, exercise units:
*Median values and interquartile ranges are shown for continuous variables and percentages for categorical variables.
{Percentages may not add up to 100 because of rounding.
{1 drink/day approximately corresponds to 12 g alcohol/day.
1Comorbidities were self-reported in response to the questions ‘‘Has a doctor or nurse ever told you that you have …’’.
||Asthma and/or chronic obstructive pulmonary disease.
"Use of oral contraceptive pills or menopausal hormone replacement therapy. The percentages given in this row are among women only.
doi:10.1371/journal.pone.0036062.t001
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time and repeated CRP elevation, even after controlling for the
use of sex hormones, which was also associated with increased odds
of both one-time and repeated CRP elevation (Table 2). High
BMI was associated with increased odds of both one-time and
repeated CRP elevation, but the magnitude of the association was
smaller in men than in women. In women, the odds of both one-
time and repeated CRP elevation increased dramatically with
BMI (Figure 1a). In fact, 69.9% of repeated elevations and 35.1%
of one-time elevations were in obese women (with BMI .30 kg/
m2), although they represented only 14.6% of the study sample.
In the 328 participants who had at least one CRP elevation
above 10 mg/L, the proportion with a one-time elevation was
only 68.6%; nearly a third of those with CRP elevations above
10 mg/L had repeated elevations. Female gender, low income,
hypertension, and high BMI were associated positively with the
odds of CRP elevation being repeated, although the magnitude of
the association with BMI was smaller in men than in women
(Table 3 and Figure 1b). The most influential predictors in the
model were BMI and gender: Their generalized Spearman
correlation coefficients with the model-predicted log odds (the
linear combination in the right hand side of the model) were 0.112
for BMI and 0.34 for gender; all other predictors had generalized
Spearman correlations (with the model-predicted log odds) that
were no greater than 0.24.
Regression tree analysis was then used to identify subgroups
with distinct risks for a CRP elevation being repeated, with the
model-predicted log odds as the outcome and BMI and gender as
predictors. (Figure 2) Three groups were identified: women with
BMI .31 kg/m2 (highest risk), men with BMI .22 kg/m2 and
women with BMI above 22 kg/m2 but no more than 31 kg/m2
(intermediate risk), and men and women with BMI ,=22 kg/m2
(lowest risk). The probability that a CRP elevation is a one-time
elevation was lowest, at 51%, in the highest risk group (women
with BMI .31 kg/m2) compared to 82% in the rest of the cohort.
Figure 3 depicts the probability of a CRP elevation being a one-
time elevation (transient elevation probability) as a function of
CRP threshold in the 3 risk groups defined by BMI and gender.
For these ‘‘BMI-gender’’ defined groups, as Table 4 illustrates,
there is considerable variability in the specific CRP thresholds
needed to achieve a given level of transient elevation probability.
In the intermediate-risk group, the probability that a CRP
elevation is a one-time elevation is 80% at the usual threshold of
10 mg/L, but in women with BMI .31 kg/m2, the probability
that a CRP elevation is a one-time elevation was 80% only at the
much higher threshold of 22 mg/L.
Discussion
In the CARDIA study, the prevalence of elevated CRP values
over 10 mg/L was 9.9%, with approximately 3% of the sample
showing repeated elevations over 10 mg/L over 13 years.
Importantly, these prevalences were generated after excluding
those who reported being sick in the 24 hours prior to
measurement. Female gender, low income, high BMI, and the
use of sex hormones were independently associated with increased
odds of repeatedly elevated CRP, relative to no CRP elevation
above 10 mg/L. Previous studies of predictors of very high
(.10 mg/L) CRP have not separated one-time CRP elevation
from repeated elevation, but identified the same risk factors [5–
7,24,25]. Consistent with previous studies, we also found that the
relationship between BMI and the odds of very high CRP (both
one-time and repeated) was not linear and was modified by gender
[5,7,14,15]. At higher levels of BMI in women, it appears that
repeated CRP elevation is almost normative.
The major new finding from this study is that female gender,
low income, high BMI and doctor-diagnosed hypertension, all
Figure 1. Predicted probabilities of C-Reactive Protein (CRP) elevation above 10 mg/L as function of body mass index (BMI). The
predicted probabilities were computed from multiple logistic regression models while all other covariates were held constant (at reference values for
categorical covariates and median values for continuous covariates). Panel A. Model-predicted probabilities of one-time and repeated CRP elevation.
Panel B. Model-predicted probabilities of exactly one-time CRP elevation among those with one or more CRP elevations above 10 mg/dL.
doi:10.1371/journal.pone.0036062.g001
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independently increased the odds of a CRP elevation being
repeated rather than one-time, with the association with BMI
being non-linear and different by gender. All these characteristics
tend to persist over time, suggesting that repeated CRP elevation
represent a result of chronic processes [26–29].
Low income and female gender are both associated with greater
levels of perceived stress [30], and chronic stress is a risk factor for
inflammation [31]. Hypertension may also serve as a marker for
chronic stress [32], as does obesity [33]. In addition, adipose tissue
is a known source of CRP in humans [34]. Chronic conditions
such as osteoarthritis, even if subclinical, are more likely in obese
persons and can lead to elevated CRP, apart from inflammation
caused directly by adipose tissue metabolism.
There are several possible explanations for our finding of gender
differences in the relationship between high BMI and repeated
CRP elevation. Higher estrogen levels may partly account for
higher CRP levels in women, since this and previous studies have
shown that exogenous estrogen therapy increases CRP levels
[35,36]. Estrogen levels are also positively associated with BMI in
women [37]. Obesity is associated with greater susceptibility to
Table 2. Multivariable-Adjusted Odds Ratio for C-Reactive Protein Elevations Above 10 mg/L.{
Characteristics
OR for one-time elevation above
10 mg/L{
OR for repeated elevation above
10 mg/L{
(95% CI) (95% CI)
Age (per year) 1.02 (0.98,1.07) 0.99 (0.93,1.05)
Gender (ref: female)
male 0.47 (0.32,0.71)*** 0.29 (0.12,0.70)**
Race (ref: Caucasian)
African-American 1.33 (0.96,1.84) 1.46 (0.86,2.47)
Income(ref: ,25 K/year)
25–50 K/year 0.97 (0.68,1.37) 0.57 (0.35,0.96)*
50–75 K/year 0.83 (0.52,1.34) 0.43 (0.19,0.97)*
.75 K/year 0.72 (0.40,1.29) 0.11 (0.01,0.89)*
Education(ref: high school)
college 0.89 (0.63,1.26) 1.02 (0.61,1.71)
graduate school 1.22 (0.75,2.01) 0.90 (0.36,2.25)
Smoking status (ref: never smoker)
current smoker 1.49 (1.03,2.17)* 1.26 (0.72,2.23)
former smoker 1.56 (1.05,2.32)* 0.88 (0.44,1.75)
Physical activity (per 100 EU) 0.98 (0.92,1.04) 0.93 (0.83,1.04)
Alcohol(ref: non-drinker)
,1 glass a day 0.89 (0.62,1.30) 0.78 (0.43,1.42)
.1 glass a day 1.12 (0.77,1.65) 0.98 (0.52,1.87)
BMI (per kg/m2){ 1.14 (1.09,1.18)*** 1.35 (1.25,1.45)***
BMI squared{ 0.998 (0.996,0.999)* 0.993 (0.990,0.996)***
Male*BMI (per kg/m2){|| 0.94 (0.87,1.02) 0.76 (0.65,0.89)***
Male*BMI-squared{|| 1.008 (1.002,1.013)** 1.017 (1.009,1.026)***
Comorbidities
hypertension 0.96 (0.58,1.59) 1.69 (0.91,3.14)
diabetes mellitus 1.07 (0.54,2.13) 0.57 (0.20,1.57)
hyperlipidemia 0.93 (0.59,1.48) 1.15 (0.58,2.26)
respiratory conditions 1.27 (0.83,1.95) 1.39 (0.75,2.56)
cancer 1.17 (0.46,2.97) 1
Medication use
sex hormones 1.90 (1.26,2.86)** 2.43 (1.34,4.43)**
aspirin 0.85 (0.37,1.95) 0.48 (0.11,2.22)
anti-hypertensives 0.46 (0.12,1.71) 0.66 (0.19,2.27)
Abbreviations; K, 1,000: BMI, body-mass index: OR, odds ratio: CI, confidence intervals: EU, exercise units:
*, **, *** denotes significance at 5%, 1%, 0.1% level, respectively.
{Multinomial logistic regression was used to calculate adjusted odds ratio, which is the ratio of odds of having either one-time or repeated CRP elevation (.10 mg/L)
relative to the odds of having no CRP elevation (reference group). All predictors were measured at the initial CRP evaluation visit.
{BMI is centered at the overall sample mean (26.7).
1There is no observation with history of cancer and repeated CRP elevation.
||Male*BMI denotes the interaction between male gender and BMI; male*BMI-squared is the interaction between male gender and the square of BMI.
doi:10.1371/journal.pone.0036062.t002
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infections [38], and therefore obesity-associated increase in
frequency of infection may contribute to obesity-associated
recurring increases in CRP. Whether there is any gender
difference in obesity-associated susceptibility to infection warrants
further research. Leptin, a hormone produced by adipose tissue, is
higher in women compared with men, which may mediate some of
the sex differences in the obesity-inflammation association [14,39].
Gender differences in fat distribution, such as the greater
accumulation of subcutaneous fat in women than in men which
partially accounts for gender differences in CRP levels [40], may
also play a role.
This study also demonstrated that the probability of a CRP
measurement above 10 mg/L being one-time (transient) elevation
varied significantly across subgroups, with the transient elevation
probability being lowest (only 51%) in obese women (with BMI
.31 kg/m2). To get transient elevation probabilities of 80%, the
CRP threshold should be 22 mg/L in obese women.
Our study has some note-worthy limitations. First, CRP
measurements were excluded in those who reported having been
sick during the 24 hours preceding their blood draw; but since
CRP levels stay elevated for 7 to 12 days after an acute
inflammatory condition [41], the 24-hour look-back period may
not be sufficient. However, under 2% of the analytic sample had
acute inflammation (with one CRP measurement above 10 mg/L
and others 3 mg/L or lower), suggesting that the 24-hour
retrospective report excluded most individuals with acute
inflammation. Second, we did not account for the temporal
ordering of CRP measurements in our analyses, which leaves open
the possibility that an isolated CRP elevation in year 20 represents
new-onset chronic inflammation, not transient acute CRP
elevation. But, the prevalence of CRP elevation above 10 mg/L
did not increase with age (see table 1 and 2) or time/year. In
addition, among those with CRP .10 mg/L in year 20, the
proportion with repeated elevation was comparable to that in
years 7 and 15 (data not shown), suggesting that we are not
underestimating persistence of CRP elevation in year 20. Third,
repeatedly elevated measurements of CRP could, in some
participants, represent recurring acute inflammation rather than
chronic inflammation; we could not distinguish between the two
from three CRP measurements spread out over 13 years, and
discounted the possibility of recurring acute inflammation. It
should be noted however, that the risk factors identified here,
namely, female gender, low income, high BMI and doctor-
diagnosed hypertension may be associated with recurring acute
inflammation rather than chronic inflammation – a question that
requires considerably more detailed longitudinal data than are
currently available through CARDIA. Lastly technical error in
CRP measurement was fairly large in the study; while this could
have led to some spurious elevations above 10 mg/L, it is unlikely
that a person whose true value was several mg/L lower than 10
would have an observed value .10 mg/L.
Table 3. Multivariable-Adjusted Odds Ratio for Repeated CRP
Elevation Above 10 mg/L Among Those With at Least one
CRP Elevation Above 10 mg/L*.
Characteristics OR (95%CI) P value
Male 0.21 (0.07,0.57) .002
Income (ref: ,25 K/year)
25 K-50 K/year 0.58 (0.32,1.03) 0.06
50 K - 75 K/year 0.45 (0.18,1.10) 0.08
. 75 K/year 0.09 (0.01,0.80) 0.03
Hypertension 2.26 (1.09,4.65) 0.03
BMI (kg/m2){ 1.13 (1.07,1.19) ,.001
Male*BMI{{ 0.904 (0.819,0.997) 0.04
BMI squared{ 0.994 (0.990,0.998) 0.002
Male*BMI-squared{{ 1.010 (1.002,1.018) 0.02
Abbreviations; K, 1,000: BMI, body-mass index: OR, odds ratio: CI, confidence
intervals:
*Multiple logistic regression was used to calculate the adjusted odds ratios.
{BMI is centered at the mean (32.4) of those with at least one CRP elevation.
{Male*BMI denotes the interaction between male gender and BMI; male*BMI-
squared is the interaction between male gender and the square of BMI.
doi:10.1371/journal.pone.0036062.t003
Figure 2. Risk stratification by baseline body mass index (BMI) and gender. Regression tree analysis was performed for the log odds of a
CRP elevation being repeated (as predicted by the logistic regression model) with BMI and gender as predictors.
doi:10.1371/journal.pone.0036062.g002
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Despite these limitations, our results have important implica-
tions for both clinical uses of CRP and epidemiological and clinical
research studies on CRP. We have made several novel findings.
We demonstrated that a significant proportion of people who do
not report being sick (in the last 24 hours) have levels of CRP over
10 mg/L, which persist (or are at least, recurring) over 13 years.
While our results are confirmatory that female gender, high BMI,
sex hormone use and low income are chronic factors that are
associated with CRP over 10 mg/L at a single cross-sectional
timepoint, we also find that these chronic factors contribute to
persistent elevated levels of CRP. These findings suggest that the
current convention in research studies of excluding anyone with
CRP .10 mg/L likely excludes many with chronic inflammation
who are at the highest risk for poor health outcomes, and likely
introduces bias into study findings.
We propose that epidemiologic studies that rely on a single
measurement of CRP should not automatically discount all
measurements above 10 mg/L as indicators of acute inflamma-
tion. Ideally, CRP should be measured repeatedly. If repeated
measurements are not feasible and only a one-time measurement
of CRP is available, participant-specific thresholds may be called
for. In particular, a CRP threshold higher than 10 mg/L is needed
to distinguish acute from chronic inflammation in obese women.
Figure 3. Probability of above-threshold CRP elevations being transient (one-time elevations), as function of CRP threshold.
Probabilities in strata defined by gender and body mass index (BMI) were shown.
doi:10.1371/journal.pone.0036062.g003
Table 4. CRP Thresholds (in mg/L) Required to Achieve Varying Probabilities of Above-Threshold Elevations Being One-Time
(Transient Elevation Probabilities) in Sub-Groups Defined by BMI and Gender.
Desired transient
elevation probability
CRP threshold needed in
low-risk group (BMI #22 kg/m2)
CRP threshold needed in intermediate-risk
group (Men with BMI .22 and women
with BMI .22 and #31 kg/m2)
CRP threshold needed in high-risk
group (Women with BMI .31 kg/m2)
70% 4.4 6.5 16.8
75% 5.4 8.8 21.3
80% 7.7 10.0 22.1
85% 8.3 14.6 22.9
90% 9.4 19.7 27.8
95% 11.4 20.7 42.7
doi:10.1371/journal.pone.0036062.t004
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